Neurotrophic factors and their inhibitors in chronic pain treatment

Neurobiology of Disease

Volumn 97, Issue , 2017, Pages 127-138

  Kelleher, Jayne H ^a   Tewari, Damini ^a   McMahon, Stephen B ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical trial; IL6; NGF; Pain

Indexed keywords

ANALGESIC AGENT; INTERLEUKIN 6; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN RECEPTOR P75; PROTEIN TYROSINE KINASE A;

ANALGESIA; CHRONIC PAIN; HUMAN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; REVIEW; SENSITIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ANIMALS; CHRONIC PAIN; HUMANS; INTERLEUKIN-6; NERVE GROWTH FACTOR;

EID: 84963665066     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.03.025     Document Type: Review

References (124)

1. Akira, S., Kishimoto, T., IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol. Rev. 127:127 (1992), 25–50, 10.1111/j.1600-065X.1992.tb01407.x.
2. Akira, S., Nishio, Y., Inoue, M., Wang, X.J., Wei, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., Kishimoto, T., Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77 (1994), 63–71, 10.1016/0092-8674(94)90235-6.
3. Aloe, Luigi, Rocco, Maria Luisa, Bianchi, Patrizia, Manni, Luigi, Nerve growth factor: from the early discoveries to the potential clinical use. J. Transl. Med., 10(January), 2012, 239, 10.1186/1479-5876-10-239.
4. Alvarez, Pedro, Levine, Jon D., Screening the role of pro-nociceptive molecules in a rodent model of endometriosis pain. The Journal of Pain : Official Journal of the American Pain Society, April, 2014, Elsevier, Ltd., 10.1016/j.jpain.2014.04.002.
5. Andratsch, Manfred, Mair, Norbert, Constantin, Cristina Elena, Scherbakov, Nadja, Benetti, Camilla, Quarta, Serena, Vogl, Christian, et al. A key role for gp130 expressed on peripheral sensory nerves in pathological pain. J. Neurosci. 29:43 (2009), 13473–13483, 10.1523/JNEUROSCI.1822-09.2009.
6. Bäckryd, Emmanuel, Ghafouri, Bijar, Larsson, Britt, Gerdle, Björn, Plasma pro-inflammatory markers in chronic neuropathic pain: a multivariate, comparative, cross-sectional pilot study. Scand. J. Pain 10 (2016), 1–5, 10.1016/j.sjpain.2015.06.006 (Elsevier B.V).
7. Bannwarth, Bernard, Kostine, Marie, Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?. Drugs, 2014, 10.1007/s40265-014-0208-6 (no. March 2012 (April)).
8. Beigelman, Avraham, Levy, Jacov, Hadad, Nurit, Pinsk, Vered, Haim, Alon, Fruchtman, Yariv, Levy, Rachel, Abnormal neutrophil chemotactic activity in children with congenital insensitivity to pain with anhidrosis (CIPA): the role of nerve growth factor. Clin. Immunol. 130:3 (2009), 365–372, 10.1016/j.clim.2008.09.005 (Elsevier Inc.).
9. Bennett, David L.H., Averill, Sharon, Clary, Douglas, Priestleyl, John V., Mcmahon, Stephen B., SHORT COMMUNICATION Postnatal changes in the expression of the trkA high-affinity NGF receptor in primary sensory neurons. Eur. J. Neurosci. 8:March (1996), 2204–2208.
10. Bennett, David L.H., Koltzenburg, Martin, Priestleyl, John V., Shelton, David L., McMahon, Stephen B., Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat. Eur. J. Neurosci. 10:4 (1998), 1282–1291, 10.1046/j.1460-9568.1998.00139.x.
11. Bergmann, I., Priestley, J.V., McMahon, S.B., Bröcker, E.B., Toyka, K.V., Koltzenburg, M., Analysis of cutaneous sensory neurons in transgenic mice lacking the low affinity neurotrophin receptor p75. Eur. J. Neurosci. 9:1 (1997), 18–28.
12. Boucher, Timothy J., Okuse, Kenji, Bennett, David L.H., Munson, John B., Wood, John N., McMahon, Stephen B., Potent analgesic effects of GDNF in neuropathic pain states. Science 290:5489 (2000), 124–127, 10.1126/science.290.5489.124.
13. Bouhassira, Didier, Lanteri-Minet, Michel, Attal, Nadine, Laurent, Bernard, Touboul, Chantal, Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136 (2008), 380–387, 10.1016/j.pain.2007.08.013.
14. Breivik, Harald, Collett, Beverly, Ventafridda, Vittorio, Cohen, Rob, Gallacher, Derek, Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur. J. Pain 10:4 (2006), 287–333, 10.1016/j.ejpain.2005.06.009.
15. Brenn, Daniel, Richter, Frank, Schaible, Hans-Georg, Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain. Arthritis Rheum. 56:1 (2007), 351–359, 10.1002/art.22282.
16. Brown, Mark T., Murphy, Frederick T., Radin, David M., Davignon, Isabelle, Smith, Michael D., West, Christine R., Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J. Pain 13:8 (2012), 790–798, 10.1016/j.jpain.2012.05.006 (Elsevier Ltd).
17. Capsoni, Simona, Cattaneo, Antonino, On the molecular basis Linking nerve growth factor (NGF) to Alzheimer's disease. Cell. Mol. Neurobiol. 26:4–6 (2006), 617–631, 10.1007/s10571-006-9112-2.
18. Capsoni, Simona, Covaceuszach, Sonia, Marinelli, Sara, Ceci, Marcello, Bernardo, Antonietta, Minghetti, Luisa, Ugolini, Gabriele, Pavone, Flaminia, Cattaneo, Antonino, Taking pain out of NGF: a ‘painless’ NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity. PLoS One, 6(2), 2011, e17321, 10.1371/journal.pone.0017321.
19. Carvalho, Ofélia P., Thornton, Gemma K., Hertecant, Joseph, Houlden, Henry, Nicholas, Adeline K., Cox, James J., Rielly, Mary, Al-Gazali, Lihadh, Woods, C. Geoffrey, A novel NGF mutation clarifies the molecular mechanism and extends the phenotypic spectrum of the HSAN5 neuropathy. J. Med. Genet. 48:2 (2011), 131–135, 10.1136/jmg.2010.081455.
20. Cohen, Stanley, Purification of a nerve-growth promoting protein from the mouse salivary gland and its neuro-cytotoxic antiserum*. Proc. Natl. Acad. Sci. U. S. A. 46:3 (1960), 302–311, 10.1073/pnas.46.3.302.
21. Cohen, Stanley, Levi-Montalcini, Rita, Hamburger, Viktor, A nerve growth-stimulating factor isolated from sarcomas 37 and 180. Proc. Natl. Acad. Sci. U. S. A. 42:9 (1954), 571–574, 10.1073/pnas.42.9.571.
22. Crowley, C., Spencer, S.D., Nishimura, M.C., Chen, K.S., Pitts-Meek, S., Armanini, M.P., Ling, L.H., McMahon, S.B., Shelton, D.L., Levinson, a D., Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 76:6 (1994), 1001–1011 ( http://www.ncbi.nlm.nih.gov/pubmed/8137419).
23. Davies, Andrew L., Hayes, Keith C., Dekaban, Gregory a, Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch. Phys. Med. Rehabil. 88:11 (2007), 1384–1393, 10.1016/j.apmr.2007.08.004.
24. De Jongh, Raf, F., Vissers, Kris C., Meert, Theo F., Booij, Leo H.D.J., De Deyne, Catharina S., Heylen, Rene J., The role of interleukin-6 in nociception and pain. Anesth. Analg. 130 (2003), 1096–1103, 10.1213/01.ANE.0000055362.56604.78.
25. DeLeo, Joyce A., Colburn, Raymond W., Nichols, Michelle, Malhortra, Amit, Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J. Interf. Cytokine Res. 16 (1996), 695–700.
26. Detloff, Megan Ryan, Fisher, Lesley C., Mcgaughy, Violetta, Longbrake, Erin E., Popovich, Phillip G., Basso, D. Michele, Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats. Exp. Neurol. 212:2 (2008), 337–347, 10.1016/j.expneurol.2008.04.009.Remote.
27. Dong, S., Sun, Y., Lu, P., Wang, Y., Wu, G., Electroacupuncture and lumbar transplant of GDNF-secreting fibroblasts synergistically attenuate hyperalgesia after sciatic nerve constriction. Am. J. Chin. Med. 41:3 (2013), 459–472.
28. Dubin, Adrienne E., Patapoutian, Ardem, Review series nociceptors : the sensors of the pain pathway. J. Clin. Invest. 120:11 (2010), 3760–3772, 10.1172/JCI42843.3760.
29. Ebbinghaus, Matthias, Banchet, Gisela Segond Von, Massier, Julia, Gajda, Mieczyslaw, Bräuer, Rolf, Kress, Michaela, Schaible, Hans-georg, Interleukin-6-dependent influence of nociceptive sensory neurons on antigen-induced arthritis. Arthritis Res. Ther., 2015, 1–13, 10.1186/s13075-015-0858-0.
30. Ebenezer, Gigi J., McArthur, Justin C., Thomas, Diane, Murinson, Beth, Hauer, Peter, Polydefkis, Michael, Griffin, John W., Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain J. Neurol. 130:Pt 10 (2007), 2703–2714, 10.1093/brain/awm199.
31. Elitt, Christopher M., McIlwrath, Sabrina L., Lawson, Jeffery J., Malin, Sacha a, Molliver, Derek C., Cornuet, Pamela K., Koerber, H. Richard, Davis, Brian M., Albers, Kathryn M., Artemin overexpression in skin enhances expression of TRPV1 and TRPA1 in cutaneous sensory neurons and leads to behavioral sensitivity to heat and cold. J. Neurosci. 26:33 (2006), 8578–8587, 10.1523/JNEUROSCI.2185-06.2006.
32. Erta, María, Quintana, Albert, Hidalgo, Juan, Interleukin-6, a major cytokine in the central nervous system., 8, 2012, 1254–1266, 10.7150/ijbs.4679.
33. Flatters, Sarah J.L., Fox, Alyson J., Dickenson, Anthony H., Spinal interleukin-6 (IL-6) inhibits nociceptive transmission following neuropathy. Brain Res. 984:1–2 (2003), 54–62, 10.1016/S0006-8993(03)03092-0.
34. Ford, Anthony P., In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal 8:Suppl. 1 (2012), 3–26, 10.1007/s11302-011-9271-6.
35. Frieling, J.T., Sauerwein, R.W., Wijdenes, J., Hendriks, T., van der Linden, C.J., Soluble interleukin 6 receptor in biological fluids from human origin. Cytokine 6:4 (1994), 376–381 ( http://www.ncbi.nlm.nih.gov/pubmed/7948745).
36. Gadient, Reto A., Otten, Uwe H., Interleukin-6 (IL-6)–a molecule with both beneficial and destructive potentials. Prog. Neurobiol. 52 (1997), 379–390.
37. Gearing, D.P., Comeau, M.R., Friend, D.J., Gimpel, S.D., Thut, C.J., McGourty, J., Brasher, K.K., King, J. a, Gillis, S., Mosley, B., The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science (New York, N.Y.) 255:5050 (1992), 1434–1437, 10.1126/science.1542794.
38. Gosselin, D., Link, V.M., Romanoski, C.E., Fonseca, G.J., Eichenfield, D.Z., Spann, N.J., Stender, J.D., et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 159:6 (2014), 1327–1340, 10.1016/j.cell.2014.11.023 (Elsevier Inc.).
39. Hall, Gillian C., Morant, Steve V., Carroll, Dawn, Gabriel, Zahava L., McQuay, Henry J., An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Fam. Pract., 14(1), 2013, 28, 10.1186/1471-2296-14-28.
40. Hama, T., Kushima, Y., Miyamoto, M., Kubota, M., Takei, N., Hatanaka, G., Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience 40:2 (1991), 445–452, 10.1016/0306-4522(91)90132-8.
41. He, Xiao-lin, Garcia, K. Christopher, Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. Science 304:May (2004), 870–875.
42. Hempstead, Barbara L., Commentary: regulating proNGF action: multiple targets for therapeutic intervention. Neurotox. Res. 16:3 (2009), 255–260, 10.1007/s12640-009-9054-9.
43. Hertz, Sharon, Fields, Ellen, FDA Center for Drug Evaluation and Research Division of Anesthesia, Analgesia, and Addiction Products. 2012.
44. Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T., Kishimoto, T., Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63 (1990), 1149–1157, 10.1016/0092-8674(90)90411-7.
45. Hoke, A., Augmenting glial cell-line derived neurotrophic factor signaling to treat painful neuropathies. Proc. Natl. Acad. Sci. 111:6 (2014), 2060–2061, 10.1073/pnas.1324047111.
46. Holmes, David, “Anti-NGF painkillers back on track?” Nature reviews drug discovery 11 (5). Nat. Publ. Group, 2012, 337–338, 10.1038/nrd3732.
47. Honda, M., Yamamoto, M., Cheng, M., Yasukawa, K., Suzuki, H., Saito, T., Osugi, Y., Tokunaga, T., Kishimoto, T., Human soluble IL-6 receptor : its detection and enhanced release by HIV infection. J. Immunol. 148 (1992), 2175–2180.
48. Horiuchio, Sankichi, Koyanagio, Yoshio, Zhouo, Yongwei, Miyamotoo, Hirokuni, Wakia, Michmori, Matsumotod, Akiyoshi, Yamamotoo, Mikio, et al. Soluble interleukin-6 receptors released from T cell. Eur. J. Immunol. 24 (1994), 1945–1948.
49. Hunter, Christopher A., Jones, Simon A., IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16:5 (2015), 448–457, 10.1038/ni.3153 (Nature Publishing Group).
50. Indo, Y., Nerve growth factor and the physiology of pain: lessons from congenital insensitivity to pain with anhidrosis. Clin. Genet. 82:4 (2012), 341–350, 10.1111/j.1399-0004.2012.01943.x.
51. Indo, Yasuhiro, Tsuruta, Motoko, Hayashida, Yumi, Karim, Mohammad Azharul, Ohta, Kohji, Kawano, Tomoyasu, Mitsubuchi, Hiroshi, Tonoki, Hidefumi, Awaya, Yutaka, Mutsuda, Ichiro, Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat. Genet. 13 (1996), 485–488.
52. Jiang, Yuan-Hong, Liu, Hsin-Tzu, Kuo, Hann-Chorng, Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid. PLoS One, 9(3), 2014, e91609, 10.1371/journal.pone.0091609.
53. Jimenez-Andrade, Juan Miguel, Ghilardi, Joseph R., Castañeda-Corral, Gabriela, Kuskowski, Michael a., Mantyh, Patrick W., Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain 152:11 (2011), 2564–2574, 10.1016/j.pain.2011.07.020 (International Association for the Study of Pain).
54. Jüttler, Eric, Tarabin, Victoria, Schwaninger, Markus, Interleukin-6 (IL-6): a possible neuromodulator induced by neuronal activity. Neuroscientist 8:3 (2002), 268–275, 10.1177/10758402008003012.
55. Kerr, B.J., Bradbury, E.J., Bennett, D.L., Trivedi, P.M., Dassan, P., French, J., Shelton, D.B., McMahon, S.B., Thompson, S.W., Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J. Neurosci. 19:12 (1999), 5138–5148 http://www.ncbi.nlm.nih.gov/pubmed/10366647.
56. Kiefer, Reinhard, Kieseier, Bernd C., Stoll, Guido, Hartung, Hans-Peter, The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog. Neurobiol. 64:2 (2001), 109–127, 10.1016/S0301-0082(00)00060-5.
57. Kiris, E., Wang, T., Yanpallewar, S., Dorsey, S.G., Becker, J., Bavari, S., Palko, M.E., Coppola, V., Tessarollo, L., TrkA in vivo function is negatively regulated by ubiquitination. J. Neurosci. 34:11 (2014), 4090–4098, 10.1523/JNEUROSCI.4294-13.2014.
58. Lacroix, Marine, Rousseau, François, Guilhot, Florence, Malinge, Pauline, Magistrelli, Giovanni, Herren, Suzanne, Jones, Simon A., et al. Novel insights into interleukin 6 (IL-6) Cis- and transsignaling pathways by differentially manipulating the assembly of the IL-6 signaling complex. J. Biol. Chem. 290:45 (2015), 26943–26953, 10.1074/jbc.M115.682138.
59. Lallemend, Francois, Ernfors, Patrik, Molecular interactions underlying the specification of sensory neurons. Trends Neurosci. 35:6 (2012), 373–381, 10.1016/j.tins.2012.03.006 (Elsevier Ltd).
60. Lane, Nancy E., Schnitzer, Thomas J., Birbara, Charles a, Mokhtarani, Masoud, Shelton, David L., Smith, Mike D., Brown, Mark T., Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363:16 (2010), 1521–1531, 10.1056/NEJMoa0901510.
61. Latremoliere, Alban, Woolf, Clifford J., Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J. Pain 10:9 (2009), 895–926, 10.1016/j.jpain.2009.06.012.Central.
62. Lavin, Yonit, Winter, Deborah, Blecher-gonen, Ronnie, David, Eyal, Keren-shaul, Hadas, Merad, Miriam, Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159:6 (2014), 1312–1326, 10.1016/j.cell.2014.11.018 (Elsevier Inc.).
63. Lee, K.F., Li, E., Huber, L.J., Landis, S.C., Sharpe, a H., Chao, M.V., Jaenisch, R., Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell 69:5 (1992), 737–749 ( http://www.ncbi.nlm.nih.gov/pubmed/1317267).
64. Leite, Victor F., Buehler, Anna M., El Abd, Omar, Benyamin, Ramsin M., Pimentel, Daniel C., Chen, Janini, Hsing, Wu Tu, Mazloomdoost, Danesh, Amadera, Joao E.D., Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis. Pain Physician 17:1 (2014), E45–E60 ( http://www.ncbi.nlm.nih.gov/pubmed/24452657).
65. Levi-montalcini, Rita, The nerve growth factor: thirty-five years later. EMBO J., 6(9), 1987, 2856 ( http://www.ncbi.nlm.nih.gov/pubmed/16453797).
66. Lewin, Gary R., Ritter, Amy M., Mendell, M., Nerve growth factor-induced adult rat hyperalgesia in the neonatal and adult rat. J. Neurosci. 13:5 (1993), 2136–2148.
67. Lissilaa, Rami, Buatois, Vanessa, Magistrelli, Giovanni, Williams, Anwen S., Jones, Gareth W., Herren, Suzanne, Shang, Limin, et al. Although Il-6 transignaling is suffiecient to drive local immune responses, classical IL-6 signaling is obligaate for the induction of T cell-mediated autoimmunity. Eur. J. Immunol., 2010, 5512–5521, 10.4049/jimmunol.1002015.
68. Liu, Xiao, Jones, Gareth W., Choy, Ernest H., Jones, Simon A., The biology behind interleukin-6 targeted interventions. Curr. Opin. Rheumatol. 28:2 (2016), 152–160, 10.1097/BOR.0000000000000255.
69. Malin, S.A., Molliver, D.C., Koerber, H.R., Cornuet, P., Frye, R., Albers, K.M., Davis, B.M., Glial cell line-derived neurotrophic factor family members sensitize nociceptors in vitro and produce thermal hyperalgesia in vivo. J. neurosci. 26:33 (2006), 8588–8599.
70. Malin, Sacha a, Davis, Brian M., Molliver, Derek C., Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. Nat. Protoc. 2:1 (2007), 152–160, 10.1038/nprot.2006.461.
71. März, P., Cheng, J.G., Gadient, R. a, Patterson, P.H., Stoyan, T., Otten, U., Rose-John, S., Sympathetic neurons can produce and respond to interleukin 6. Proc. Natl. Acad. Sci. U. S. A. 95:6 (1998), 3251–3256, 10.1073/pnas.95.6.3251.
72. McCaffrey, Gwen, Thompson, Michelle L., Majuta, Lisa, Fealk, Michelle N., Chartier, Stephane, Longo, Geraldine, Mantyh, Patrick, NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use. Cancer Res., 2014 October, 10.1158/0008-5472.CAN-14-1220.
73. McKinnon, Brett D., Bertschi, Dominic, Bersinger, Nick A., Mueller, Michael D., Inflammation and nerve fiber interaction in endometriotic pain. Trends Endocrinol. Metab. 26:1 (2015), 1–10, 10.1016/j.tem.2014.10.003 (Elsevier Ltd).
74. McMahon, Stephen B., Bennett, David L.H., Priestleyl, John V., Shelton, David L., The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat. Med. 1:8 (1995), 774–780.
75. McMahon, Stephen B., Koltzenburg, Martin, Tracey, Irene, Turk, Dennis, Wall and Melzack's Textbook of Pain. sixth ed, 2013, Elsevier (Chapter 3).
76. Meeker, Rick, Williams, Kimberly, Dynamic nature of the p75 neurotrophin receptor in response to injury and disease. J. NeuroImmune Pharmacol., 2014 September, 10.1007/s11481-014-9566-9.
77. Michael, G.J., Averill, S., Nitkunan, A., Rattray, M., Bennett, D.L., Yan, Q., Priestley, J.V., Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J. Neurosci. 17:21 (1997), 8476–8490 http://www.ncbi.nlm.nih.gov/pubmed/9334420.
78. Mo, Alisa, Mukamel, Eran A., Davis, Fred P., Luo, Chongyuan, Henry, Gilbert L., Picard, Serge, Urich, Mark A., et al. Epigenomic signatures of neuronal diversity in the mammalian brain. Neuron 86:6 (2015), 1369–1384, 10.1016/j.neuron.2015.05.018.
79. Moalem, Gila, Tracey, David J., Immune and inflammatory mechanisms in neuropathic pain. Brain Res. Rev. 51:2 (2006), 240–264, 10.1016/j.brainresrev.2005.11.004.
80. Mukaino, Masahiko, Nakamura, Masaya, Yamada, Osamu, Okada, Seiji, Morikawa, Satoru, Renault-Mihara, Francois, Iwanami, Akio, et al. Anti-IL-6-receptor antibody promotes repair of spinal cord injury by inducing microglia-dominant inflammation. Exp. Neurol. 224:2 (2010), 403–414, 10.1016/j.expneurol.2010.04.020 (Elsevier Inc.).
81. Mullard, Asher, Drug developers reboot anti-NGF pain programmes. Nat. Rev. Drug Discov. 14:5 (2015), 297–298, 10.1038/nrd4612 (Nature Publishing Group).
82. Müllberg, J., Schooltink, H., Stoyan, T., Günther, M., Graeve, L., Buse, G., Mackiewicz, A., Heinrich, P.C., Rose-John, S., The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 23 (1993), 473–480, 10.1002/eji.1830230226.
83. Murphy, P.G., Ramer, M.S., Borthwick, L., Gauldie, J., Richardson, P.M., Bisby, M.A., Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides associated with chronic nerve constriction in mice. Eur. J. Neurosci. 11 (1999), 2243–2253, 10.1046/j.1460-9568.1999.00641.x.
84. Narazaki, By Masashi, Yasukawa, Kiyoshi, Saito, Takashi, Ohsugi, Yoshiyuki, Fukui, Hiroyasu, Koishihara, Yasuo, Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82:4 (1993), 1120–1126.
85. Novick, D., Engelmann, H., Wallach, D., Rubinstein, M., Soluble cytokine receptors are present in normal human urine. J. Exp. Med. 170:October (1989), 1409–1414, 10.1084/jem.170.4.1409.
86. Oh, J.W., Van Wagoner, N.J., Rose-John, S., Benveniste, E.N., Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression. J. Immunol. 161:9 (1998), 4992–4999 ( http://www.ncbi.nlm.nih.gov/pubmed/9794436).
87. Ohtori, Seiji, Miyagi, Masayuki, Eguchi, Yawara, Inoue, Gen, Orita, Sumihisa, Ochiai, Nobuyasu, Kishida, Shunji, et al. Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica. Eur. Spine J. 21:10 (2012), 2079–2084, 10.1007/s00586-012-2183-5.
88. Oka, Takakazu, Oka, Kae, Hosoi, Masako, Hori, Tetsuro, Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res. 692 (1995), 123–128.
89. Patapoutian, a, Reichardt, L.F., Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol. 11:3 (2001), 272–280 ( http://www.ncbi.nlm.nih.gov/pubmed/11399424).
90. Patapoutian, Ardem, Tate, Simon, Woolf, Clifford J., Transient receptor potential channels: targeting pain at the source. Nat. Rev. Drug Discov. 8:1 (2009), 55–68, 10.1038/nrd2757.
91. Patel, Tushar D., Jackman, Alana, Rice, Frank L., Kucera, Jan, Snider, William D., Erratum: development of sensory neurons in the absence of NGF/TrkA signaling in vivo (neuron (February 2000) 25 (345–357)). Neuron, 37(1), 2003, 183, 10.1016/S0896-6273(02)01176-5.
92. Pecchi, Emilie, Priam, Sabrina, Gosset, Marjolaine, Pigenet, Audrey, Sudre, Laure, Laiguillon, Marie-Charlotte, Berenbaum, Francis, Houard, Xavier, Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. Arthritis Res. Ther., 16(1), 2014, R16, 10.1186/ar4443.
93. Pezet, Sophie, McMahon, Stephen B., Neurotrophins: mediators and modulators of pain. Annu. Rev. Neurosci. 29:January (2006), 507–538, 10.1146/annurev.neuro.29.051605.112929.
94. Poole, S., Cunha, F.Q., Selkirk, S., Lorenzetti, B.B., Ferreira, S.H., Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br. J. Pharmacol. 115:4 (1995), 684–688.
95. Rice, Andrew S.C., Dworkin, Robert H., McCarthy, Tom D., Anand, Praveen, Bountra, Chas, McCloud, Philip I., Hill, Julie, et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 383:9929 (2014), 1637–1647, 10.1016/S0140-6736(13)62337-5 (Elsevier Ltd).
96. Richner, Mette, Ulrichsen, Maj, Elmegaard, Siri Lander, Dieu, Ruthe, Pallesen, Lone Tjener, Vaegter, Christian Bjerggaard, Peripheral nerve injury modulates neurotrophin signaling in the peripheral and central nervous system. Mol. Neurobiol., 2014 April, 10.1007/s12035-014-8706-9.
97. Schaible, H., Peripheral and central mechanisms of pain generation. Handb. Exp. Pharmacol. 177 (2006), 3–28.
98. Scheller, Jürgen, Chalaris, Athena, Schmidt-Arras, Dirk, Rose-John, Stefan, The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta, Mol. Cell Res. 1813 (2011), 878–888, 10.1016/j.bbamcr.2011.01.034.
99. Scholz, Joachim, Woolf, Clifford J., The neuropathic pain triad: neurons, immune cells and glia. Nat. Neurosci. 10:11 (2007), 1361–1368, 10.1038/nn1992.
100. Schwertner, André, Santos, Claudia C. Conceição Dos, Costa, Gislene Dalferth, Deitos, Alícia, de Souza, Andressa, de Souza, Izabel Cristina Custodio, Torres, Iraci L.S., da Cunha Filho, João Sabino L., Caumo, Wolnei, Efficacy of melatonin in the treatment of endometriosis: a phase II, randomized, double-blind, placebo-controlled trial. Pain 154:6 (2013), 874–881, 10.1016/j.pain.2013.02.025 (International Association for the Study of Pain).
101. Sevcik, Molly A., Ghilardi, Joseph R., Peters, Christopher M., Lindsay, Theodore H., Halvorson, Kyle G., Jonas, Beth M., Kubota, Kazufumi, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115:1–2 (2005), 128–141, 10.1016/j.pain.2005.02.022.
102. Simpson, Richard J., Hammacher, Annet, Smith, David K., Hews, Jacqueline M. Mati, Ward, Larry D., Interleukin-6 : structure-function relationships. Protein Sci. 6 (1997), 929–955.
103. Smeyne, Richard J., Klein, Rudiger, Schnapp, Andreas, Long, Linda K., Bryant, Sherri, Lewin, Anne, Lira, Sergio A., Barbacid, Mariano, Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature 370 (1994), 621–628.
104. Smith, P., Hobisch, A., Lin, D., Culig, Z., Keller, E., Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 12:1 (2001), 33–40, 10.1016/S1359-6101(00)00021-6.
105. Snider, William D., McMahon, Stephen B., Tackling pain at the source: new ideas about nociceptors. Neuron 20 (1998), 629–632, 10.1016/S0896-6273(00)81003-X.
106. Taga, Tetsuya, Kishimoto, Tadamitsu, GP130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15:1 (1997), 797–819, 10.1146/annurev.immunol.15.1.797.
107. Thakur, Matthew, Crow, Megan, Richards, Natalie, Davey, Gareth I.J., Levine, Emma, Kelleher, Jayne H., Agley, Chibeza C., Denk, Franziska, Harridge, Stephen D.R., McMahon, Stephen B., Defining the nociceptor transcriptome. Front. Mol. Neurosci., 7(November), 2014, 87, 10.3389/fnmol.2014.00087.
108. The National Academies Press, Relieving Pain in America Committee on Advancing Pain Research, Care, and Education Board on Health Sciences Policy. 2011 ( http://www.ncbi.nlm.nih.gov/books/NBK91497/pdf/TOC.pdf).
109. Theodosiou, M., Rush, R.A., Zhou, X.F., Hu, D., Walker, J.S., Tracey, D.J., Hyperalgesia due to nerve damage: role of nerve growth factor. Pain 81:3 (1999), 245–255.
110. Thier, M., Marz, P., Otten, U., Weis, J., Rose-John, S., Interleukin-6 (IL-6) and its soluble receptor support survival of sensory neurons. J. Neurosci. Res. 422:July 1998 (1999), 411–422.
111. Torres, P.M.M., de Araujo, E.G., Interleukin-6 increases the survival of retinal ganglion cells in vitro. J. Neuroimmunol. 117:1–2 (2001), 43–50 http://www.ncbi.nlm.nih.gov/pubmed/11431003.
112. Usoskin, Dmitry, Furlan, Alessandro, Islam, Saiful, Abdo, Hind, Lönnerberg, Peter, Lou, Daohua, Hjerling-Leffler, Jens, et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat. Neurosci. 18:1 (2014), 145–153, 10.1038/nn.3881 (Nature Publishing Group).
113. van Hecke, O., Torrance, N., Smith, B.H., Chronic pain epidemiology and its clinical relevance. Br. J. Anaesth. 111:1 (2013), 13–18, 10.1093/bja/aet123.
114. Vazquez, Enrique, Kahlenbach, Jan, von Banchet, Gisela Segond, König, Christian, Schaible, Hans-Georg, Ebersberger, Andrea, Spinal interleukin-6 is an amplifier of arthritic pain in the rat. Arthritis Rheum. 64:7 (2012), 2233–2242, 10.1002/art.34384.
115. Wang, Hao, Romano, Gary, Frustaci, Mary Ellen, Bohidar, Norm, Ma, Huizhong, Sanga, Panna, Ness, Seth, et al. Fulranumab for treatment of diabetic peripheral neuropathic pain: a randomized controlled trial. Neurology 83:7 (2014), 628–637, 10.1212/WNL.0000000000000686.
116. Wang, Ruizhong, Rossomando, Anthony, Sah, Dinah W.Y., Ossipov, Michael H., King, Tamara, Porreca, Frank, Artemin induced functional recovery and reinnervation after partial nerve injury. Pain 155:3 (2014), 476–484, 10.1016/j.pain.2013.11.007 (International Association for the Study of Pain).
117. Wierzbowska, a, Urbańska-Ryś, H., Robak, T., Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Br. J. Haematol. 105 (1999), 412–419.
118. Wiesmann, C., Ultsch, M.H., Bass, S.H., de Vos, A.M., Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature 401:6749 (1999), 184–188.
119. Woolf, Clifford J., Safieh-Garabedian, B., Ma, Q.P., Crilly, P., Winter, J., Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Lett. Neurosc. 62:2 (1994), 327–331.
120. Yamasaki, Katsuhiko, Taga, Tetsuya, Hirata, Yuuichi, Yawata, Hideo, Kawanishi, Yoshikazu, Seed, Brian, Taniguchi, Tadatsuga, Hirano, Toshio, Kishimoto, Tadamitsu, Cloning and expression of the human interleukin-6 cloning. Science 241:10 (1988), 825–828.
121. Yan, Jin, Melemedjian, Ohannes K., Price, Theodore J., Dussor, Gregory, Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6). Mol. Pain, 8(1), 2012, 6, 10.1186/1744-8069-8-6.
122. Yasukawa, K., Saito, T., Fukunaga, T., Sekimori, Y., Koishihara, Y., Fukui, H., Ohsugi, Y., Matsuda, T., Yawata, H., Hirano, T., Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J. Biochem. 108:4 (1990), 673–676.
123. Zhang, Guo-Jun, Adachi, Isamu, Serum interleukin-6 levels correlate to tumour progression and prognosis in metastatic breast carcinoma. Anticancer Res. 19 (1999), 1427–1432.
124. Zhong, J., Dietzel, I.D., Wahle, P., Kopf, M., Heumann, R., Sensory impairments and delayed regeneration of sensory axons in interleukin-6-deficient mice. J. Neurosci. 19:11 (1999), 4305–4313.